Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
Tumor necrosis factor alpha (TNFalpha) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles, it was thought that inhibition of TNF may aid in the treatment of certain dermatologic diseases such as psoriasis, hidradentitis suppurativa, pyoderma gangrenosum, Behcet 's syndrome, and graft versus host disease. The efficacy of these agents has proven impressive and short-term side effects have been few and relatively benign.
Trent
Jennifer T
JT
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, FL, USA.
Kerdel
Francisco A
FA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy / Q000503:physiopathology; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000503:physiopathology; D017497:Hidradenitis Suppurativa / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy / Q000503:physiopathology; D017511:Pyoderma Gangrenosum / Q000188:drug therapy / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept